Inactive Instrument

W WORL Stock

Equities

Duration

Period

Style

Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	13-01-02	CI
Pharmos Corp. Announces Management Changes	12-10-17	CI
Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-07-30	CI
Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout	12-05-17	CI
Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012	12-04-16	CI
Pharmos Corp. Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout	12-04-05	CI
Pharmos Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	12-02-17	CI

W World Corp. is a United States-based company. The Company has no operation nor generated any revenue.

Sector